Probiotics in the Prevention of C Difficile Infection

Slides:

Advertisements

Similar presentations

Introduction to Evidence Based Medicine Pediatric Clerkship LSUHSC.

Advertisements

The use of Probiotics in the prevention of Antibiotic-Associated Diarrhea Evidence Based Medicine Lindsey Bowman.

Probiotics May Lower Risk for Nosocomial Infections in Hospitalized Children A randomized, double-blind, placebo-controlled trial reported in the May issue.

Nilofar Rahman, MD RISK OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION WITH PPI USE.

Treatment duration and outcomes for male urinary tract infection (UTI) Retrospective review of 33,336 patients with index UTI from Veterans Affairs database.

R1 김동연 /prof. 이창균. Introduction  Recurrent Clostridium difficile infection is difficult to treat, and failure rates for antibiotic therapy are high.

Wan-Jie Gu, MSc, Chun-Yin Wei, MSc, Rui-Xing Yin, MD, PhD CHEST

YOUR ACTIONS PROTECT ANTIBIOTICS, RALLY TOGETHER AT

Improvement of management and reduction in mortality following implementation of audit recommendations in Clostridium difficile diarrhoea at James Cook.

Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection F. Cao, C.X. Chen, M. Wang,

Use of Probiotics in Larger Controlled Trials in Humans

Volume 152, Issue 8, Pages e9 (June 2017)

Preventing Thrombotic Complications in ACS: State of the Art

New Guidelines to Prevent SCD: What You Need to Know

NOACs for Cancer-Associated Thrombosis:

Chronic Hepatitis C Virus Infection

Omega-3 Prescriptions vs Supplements in Practice

Infection Prevention: A Hierarchy of Controls Approach

Cardiogenic Shock.

US Guidelines US Guidelines Low-risk Patients.

Update on Clostridium difficile Infection

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Select Topics in Cardiovascular Medicine

Volume 152, Issue 8, Pages e9 (June 2017)

Treatment of Complicated Intra-abdominal Infections

nAMD: Switching Therapies - what you need to know

Selecting NOACs for High-Risk Patients

Volume 152, Issue 8, Pages e9 (June 2017)

T2DM and CV Outcomes Trials: A Deep Dive!

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Statins and Glucose Metabolism: Are All Agents Alike?

Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?

Efficacy and Safety of Edoxaban in Patients With AF and HF

Growing Diabetes Pandemic Worldwide

Personalizing Statin Therapy in Patients With HIV

A Journal Club on Lipid Management:

Learning Objectives Classification of VTE Goals of VTE Treatment.

Probiotics for Prevention of Ventilator-Associated Pneumonia: Response

Statins and HIV:.

Erratum Regarding “Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials” (Am.

Practical Considerations to Extend Treatment for VTE

Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis

Learning Objectives Metabolic Abnormalities Associated With T2D.

Andrew H. Stewart, FRCS, Paul S. Eyers, FRCS, Jonothan J

Treatment Update on Clostridium difficile Infection

Aspirin and Cardioprevention in 2018

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Cancer-Associated Thrombosis

CDI Prevention Partnership Collaborative

New Strategies to Reduce HF Readmissions

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Program Goals Background: Anticoagulation in Patients With VTE.

2015 EASD In Review: CV Risk management in t2dm

C.P. Kelly Clinical Microbiology and Infection

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Evaluating the Science of Cardiogenic Shock

Antiarrhythmic Drugs in AF

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Volume 152, Issue 8, Pages e9 (June 2017)

Daily percentages of probiotic oligotype reads found in the dolphin rectum samples. Daily percentages of probiotic oligotype reads found in the dolphin.

My PAH Patient.

B-FREE Trial B-FREE Trial Summary.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Volume 153, Issue 5, Pages (November 2017)

A probiotic trial: tipping the balance of evidence?

Taking a Closer Look at Probiotic Efficacy

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Probiotics in the Prevention of C Difficile Infection

CDI Outcomes

Risk Factors for CDI

CDI Prevention Is Both Multifactorial and Multidisciplinary

Antibiotics Associated With CDI

Preventing Spread of C difficile in the Hospital

Setting the Stage for CDI

Development of CDI Is Caused By…

Probiotics as an Adjunctive Preventive Measure

Meta-Analysis of Randomized Trials for Probiotics in Primary Prevention of CDI

PLACIDE -- Lactobacillus & Bifidobacterium in Prevention of AAD and CDI

Comparative CDI Rates Pierre-Le Gardeur Hospital vs Similar Hospitals in Quebec

Proposed Mechanisms of Probiotic Action

2016 Systematic Review and Meta-Analysis

Practical Considerations

Abbreviations